Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation du lasofoxifène associé à l'abémaciclib par rapport au fulvestrant associé à l'abémaciclib dans le cancer du sein localement avancé ou métastatique ER+/HER2- avec une mutation ESR1 (ELAINEIII)

10 novembre 2026 mis à jour par: LeonaBio

Une étude ouverte, randomisée et multicentrique comparant l'efficacité et l'innocuité de l'association du lasofoxifène et de l'abémaciclib à l'association du fulvestrant et de l'abémaciclib pour le traitement des femmes et des hommes pré- et post-ménopausés atteints d'un cancer du sein ER+/HER2- localement avancé ou métastatique avec une mutation ESR1

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.

The main question the study aims to answer is:

• To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

600

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Simon Daggett - Senior Vice President, Clinical Operations
  • Numéro de téléphone: (425) 620-8772 (909) 374-3793
  • E-mail: clinicaltrials@leonabio.com

Lieux d'étude

      • Dresden, Allemagne
      • München, Allemagne
        • Recrutement
        • Klinikum rechts der Isar der Technischen Universitaet Muenchen
        • Contact:
      • Blacktown, Australie
      • Concord, Australie
        • Recrutement
        • Concord Repatriation General Hospital
        • Contact:
      • South Brisbane, Australie
        • Recrutement
        • Mater Misericordiae Ltd, South Brisbane
        • Contact:
    • Ontario
      • Ottawa, Ontario, Canada
        • Recrutement
        • The Ottawa General Hospital
        • Contact:
      • Toronto, Ontario, Canada
        • Recrutement
        • Sunnybrook Health Sciences Centre -Bayview Campus
        • Contact:
    • Quebec
      • Montreal, Quebec, Canada
      • Montreal, Quebec, Canada
      • Saguenay, Quebec, Canada
        • Retiré
        • CIUSSS du Saguenay-Lac-Saint-Jean
      • Anhui, Chine
        • Recrutement
        • Anhui Provincial Cancer Hospital
        • Contact:
      • Anyang, Chine
      • Beijing, Chine
        • Recrutement
        • Peking Union Medical College Hospital
        • Contact:
      • Beijing, Chine
        • Recrutement
        • Beijing Cancer Hospital
        • Contact:
      • Bengbu, Chine
        • Recrutement
        • The First Affiliated Hospital of Bengbu Medical University
        • Contact:
      • Changchun, Chine
        • Recrutement
        • The First Hospital of Jilin University
        • Contact:
      • Changsha, Chine
        • Recrutement
        • The Second Xiangya Hospital of Central South University
        • Contact:
      • Chengdu, Chine
        • Recrutement
        • Sichuan Provincial People's Hospital
        • Contact:
      • Chengdu, Chine
        • Recrutement
        • West China Hospital, Sichuan University
        • Contact:
      • Chongqicun, Chine
        • Recrutement
        • The First Affiliated Hospital, Chongqing Medical University
        • Contact:
      • Dalian, Chine
        • Recrutement
        • The Second Hospital of Dalian Medical University
        • Contact:
      • Deyang, Chine
        • Recrutement
        • Deyang People's Hospital
        • Contact:
      • Fuyang, Chine
        • Recrutement
        • Fuyang Cancer Hosptial
        • Contact:
      • Fuzhou, Chine
        • Recrutement
        • Fujian Cancer Hospital
        • Contact:
      • Fuzhou, Chine
        • Recrutement
        • Fujian Medical University Union Hospital
        • Contact:
      • Guandong, Chine
        • Recrutement
        • Zhujiang Hospital of Nanfang Medical University
        • Contact:
          • Guangyu Yao
          • Numéro de téléphone: 18675835626
          • E-mail: ygy531@163.com
      • Guangdong, Chine
        • Recrutement
        • Guangdong Provincial People's Hospital
        • Contact:
      • Guangdong, Chine
        • Recrutement
        • Meizhou People's Hospital
        • Contact:
      • Guangdong, Chine
        • Recrutement
        • Peking University Shenzhen Hospital
        • Contact:
          • Xiaoling Liu
      • Guangdong, Chine
        • Recrutement
        • Sun Yat-Sen University- Cancer Center
        • Contact:
      • Guangzhou, Chine
        • Recrutement
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Contact:
      • Haikou, Chine
        • Recrutement
        • The First Affiliated Hospital of Hainan Medical University
        • Contact:
      • Hangzhou, Chine
        • Recrutement
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
        • Contact:
      • Hangzhou, Chine
        • Recrutement
        • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
        • Contact:
      • Hangzhou, Chine
        • Recrutement
        • Zhejiang Provincial Hospital of Chinese Medicine
        • Contact:
      • Hebei, Chine
        • Recrutement
        • Hebei Medical University - The Fourth Hospital - Hebei Provincial Tumor Hospital
        • Contact:
      • Hubei, Chine
        • Recrutement
        • Xiangyang Central Hospital
        • Contact:
      • Hunan, Chine
        • Recrutement
        • Xiangya Hospital Central South University
        • Contact:
      • Jieyang, Chine
        • Recrutement
        • Jieyang People's Hospital
        • Contact:
      • Jinan, Chine
        • Recrutement
        • Shandong Province Tumor Hospital
        • Contact:
      • Kunming, Chine
        • Recrutement
        • Yunnan Cancer Hospital
        • Contact:
      • Lanzhou, Chine
        • Recrutement
        • The First Hospital of Lanzhou University
        • Contact:
          • Xiaoling Ling
          • Numéro de téléphone: 18693165668
          • E-mail: 86860306@qq.com
      • Lanzhou, Chine
        • Recrutement
        • Gansu Provincial Hospital
        • Contact:
      • Linyi, Chine
        • Recrutement
        • Linyi Cancer Hospital
        • Contact:
      • Luoyang, Chine
        • Recrutement
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Contact:
          • Xinshuai Wang
          • Numéro de téléphone: 13837986128
          • E-mail: xshuaiw@126.com
      • Luoyang, Chine
        • Recrutement
        • Luoyang Central Hospital
        • Contact:
      • Luzhou, Chine
        • Recrutement
        • The Affiliated Hospital of Southwest Medical University (Luzhou Medical College)
        • Contact:
      • Nanchang, Chine
        • Recrutement
        • Jiangxi Cancer Hospital
        • Contact:
      • Nanchang, Chine
        • Recrutement
        • Nanchang People's Hospital
        • Contact:
      • Nanjing, Chine
        • Recrutement
        • Nanjing Drum Tower Hospital
        • Contact:
      • Nanjing, Chine
        • Recrutement
        • Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University
        • Contact:
      • Nanning, Chine
        • Recrutement
        • Guangxi Medical University Cancer Hospital
        • Contact:
      • Nanyang, Chine
        • Recrutement
        • Nanyang Central Hospital
        • Contact:
      • Neijiang, Chine
        • Recrutement
        • The Second People's Hospital of Neijiang
        • Contact:
      • Ningbo, Chine
        • Recrutement
        • Ningbo Medical Center Li Huili Hospital
        • Contact:
      • Pingdingshan, Chine
        • Recrutement
        • The First People'S Hospital of Ping Ding Shan
        • Contact:
      • Qingdao, Chine
        • Recrutement
        • The Affiliated Hospital of Qingdao University
        • Contact:
      • Qingdao, Chine
        • Recrutement
        • Qingdao Central Hospital, University of Health and Rehabilitation Sciences
        • Contact:
      • Quanzhou, Chine
        • Recrutement
        • Quanzhou First Hospital
        • Contact:
      • Shanghai, Chine
        • Recrutement
        • Huashan Hospital, Fudan University
        • Contact:
      • Shanghai, Chine
        • Recrutement
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Contact:
      • Shang’ai, Chine
        • Recrutement
        • Fudan University Cancer Center
        • Contact:
      • Shanxi, Chine
        • Recrutement
        • First Affiliated Hospital of Xi'an Jiaotong University
        • Contact:
      • Shaoyang, Chine
        • Recrutement
        • The Central Hospital of Shaoyang
        • Contact:
      • Shenyang, Chine
        • Recrutement
        • Liaoning Cancer Hospital & Institute
        • Contact:
      • Shouguang, Chine
        • Recrutement
        • Yuebei People's Hospital
        • Contact:
      • Sichuan, Chine
        • Recrutement
        • University of Electonic Science & Technology (UESTC) - Sichuan Cancer Hospital & Institute
        • Contact:
      • Tianjin, Chine
        • Recrutement
        • Tianjin Medical University Cancer Institute & Hospital
        • Contact:
      • Tianjin, Chine
        • Recrutement
        • Tianjin Cancer Hospital Airport Hospital
        • Contact:
          • Chunfang Hao
          • Numéro de téléphone: 13602031629
          • E-mail: haochf@163.com
      • Wenzhou, Chine
        • Recrutement
        • The First Affiliated Hospital of Wenzhou Medical University
        • Contact:
          • Ouchen Wang
          • Numéro de téléphone: 13957706099
          • E-mail: woc099@163.com
      • Wuhan, Chine
        • Recrutement
        • Hubei Cancer Hospital
        • Contact:
      • Wuhan, Chine
        • Recrutement
        • Union Hospital Tongji Medical College Huazhong University of Science and Technolog
        • Contact:
      • Wuhu, Chine
        • Recrutement
        • The Second People's Hospital of WuHu
        • Contact:
      • Xi Ail, Chine
        • Recrutement
        • The First Affiliated Hospital of Air Force Medical University
        • Contact:
      • Xiamen, Chine
        • Recrutement
        • Zhongshang Hospital Xiamen University
        • Contact:
      • Xiamen, Chine
        • Recrutement
        • The first affiliated hospital of Xiamen University
        • Contact:
          • Zhong Ouyang
          • Numéro de téléphone: 18205962909
          • E-mail: oyzlyl@163.com
      • Xinzheng, Chine
        • Recrutement
        • The Second Affiliated Hospital Of Xi'an Jiaotong University
        • Contact:
      • Xuzhou, Chine
        • Recrutement
        • The Affiliated Hospital of Xuzhou Medical University
        • Contact:
          • Hongbing Wang
          • Numéro de téléphone: 15996969368
          • E-mail: hbw0316@163.com
      • Xuzhou, Chine
        • Recrutement
        • Xuzhou Central Hospital
        • Contact:
      • Yuncheng, Chine
        • Recrutement
        • Yuncheng Central Hospital
        • Contact:
      • Zhejiang, Chine
        • Recrutement
        • Zhejiang Provincial People's Hospital
        • Contact:
      • Zhejiang, Chine
        • Recrutement
        • Zhejiang cancer hospital
        • Contact:
      • Zhengzhou, Chine
        • Recrutement
        • Henan Cancer Hospital
        • Contact:
      • Zhengzhou, Chine
        • Recrutement
        • The First Affiliated Hospital of Zhengzhou University
        • Contact:
      • Zhongshan, Chine
        • Recrutement
        • Zhongshan City People's Hospital
        • Contact:
      • Zhumadian, Chine
        • Recrutement
        • Zhumadian Central Hospital
        • Contact:
      • Ürümqi, Chine
        • Recrutement
        • The Affiliated Cancer Hospital of Xinjiang Medical University
        • Contact:
      • Gyeonggi-do, Corée du Sud
        • Recrutement
        • National Cancer Center
        • Contact:
      • Jeollanam-do, Corée du Sud, 58128
        • Recrutement
        • Chonnam National University Hwasun Hospital
        • Contact:
      • Seoul, Corée du Sud
        • Recrutement
        • Korea University Anam Hospital
        • Contact:
      • Seoul, Corée du Sud
        • Retiré
        • Severance Hospital, Yonsei University Health System
      • Seoul, Corée du Sud
        • Retiré
        • Asan Medical Center
      • Barcelona, Espagne
        • Recrutement
        • Hospital Universitario Vall d'Hebron
        • Contact:
          • Miriam Arumi de Dios
          • Numéro de téléphone: +34600240679
          • E-mail: marumi@vhio.net
      • Barcelona, Espagne
      • Córdoba, Espagne
        • Recrutement
        • Hospital Universitario Reina Sofia
        • Contact:
      • Madrid, Espagne, 28034
        • Recrutement
        • Hospital Universitario Ramon y Cajal
        • Contact:
      • Madrid, Espagne, 28040
      • Madrid, Espagne
        • Recrutement
        • Hospital Universitario 12 de Octubre
        • Contact:
      • Madrid, Espagne
      • Madrid, Espagne
        • Recrutement
        • Clinica Universidad de Navarra - Madrid
        • Contact:
      • Madrid, Espagne
        • Recrutement
        • Hospital Beata Maria Ana
        • Contact:
      • Madrid, Espagne
        • Recrutement
        • Hospital General Universitario Gregorio Maranon
        • Contact:
      • Málaga, Espagne
      • Pamplona, Espagne
        • Recrutement
        • Clinica Universidad de Navarra - Pamplona
        • Contact:
      • Valencia, Espagne
        • Recrutement
        • Instituto Valenciano de Oncologia
        • Contact:
          • Angel Guerrero Zotano
          • Numéro de téléphone: +34 96 111 4051
          • E-mail: aguerrero@fivo.org
      • Afula, Israël, 1834111
      • Beersheba, Israël, 8486614
      • Haifa, Israël
      • Jerusalem, Israël
      • Jerusalem, Israël
        • Recrutement
        • Hadassah Ein-Karem Medical Center
        • Contact:
      • Kfar Saba, Israël, 4428164
      • Petah Tikva, Israël
      • Rehovot, Israël
        • Recrutement
        • Kaplan Medical Center
        • Contact:
      • Tel Aviv, Israël
        • Recrutement
        • Tel Aviv Sourasky Medical Center
        • Contact:
      • Tel HaShomer, Israël
      • Ancona, Italie
      • Aviano, Italie
      • Candiolo, Italie, 10060
      • Meldola, Italie
        • Recrutement
        • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
        • Contact:
      • Milan, Italie
      • Misterbianco, Italie
        • Recrutement
        • Humanitas Istituto Clinico Catanese
        • Contact:
      • Modena, Italie
        • Recrutement
        • Azienda Ospedaliero-Universitaria di Modena
        • Contact:
      • Naples, Italie
      • Novara, Italie, 28100
        • Retiré
        • Azienda Ospedaliero Universitaria Maggiore Della Carita
      • Padova, Italie, 35128
        • Recrutement
        • Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera
        • Contact:
      • Parma, Italie
      • Pavia, Italie
        • Recrutement
        • Fondazione IRCCS Policlinico San Matteo
        • Chercheur principal:
          • Gianpiero Rizzo
        • Contact:
      • Roma, Italie
      • Verona, Italie
        • Complété
        • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
      • Biała Podlaska, Pologne
        • Retiré
        • KO - MED Centra Kliniczne Sp. z o.o., Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
      • Gliwice, Pologne
        • Retiré
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii
      • Krakow, Pologne
        • Recrutement
        • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie - Oddzial Onkologii Klinicznej z Pododdzialem Dziennym
        • Contact:
      • Krakow, Pologne
      • Lodz, Pologne
        • Complété
        • Instytut Centrum Zdrowia Matki Polki - Klinika Onkologii
      • Poznan, Pologne
        • Recrutement
        • Uniwersytecki Szpital Kliniczny w Poznaniu, Oddzial Chemioterapii
        • Contact:
      • Poznan, Pologne
        • Recrutement
        • Wielkopolskie Centrum Onkologii (WCO) / The Greater Poland Cancer Center
        • Contact:
      • Wieliszew, Pologne
        • Recrutement
        • Mazowiecki Szpital Onkologiczny
        • Contact:
      • Bucharest, Roumanie
        • Recrutement
        • Memorial Healthcare International SRL
        • Contact:
      • Bucharest, Roumanie
        • Retiré
        • Centrul Medical Focus
      • Cluj-Napoca, Roumanie
      • Craiova, Roumanie
        • Recrutement
        • Oncology Center Sfantul Nectarie
        • Contact:
      • Craiova, Roumanie
        • Complété
        • Onco Clinic Consult SA
      • Piteşti, Roumanie
        • Recrutement
        • Gral Medical SRL
        • Contact:
      • Timișoara, Roumanie
        • Recrutement
        • OncoMed Oncology Center
        • Contact:
      • Cardiff, Royaume-Uni, CF14 2TL
      • Harlow, Royaume-Uni, CM20 1QX
        • Recrutement
        • Princess Alexandra Hospital - Harlow
        • Contact:
      • Leeds, Royaume-Uni
      • London, Royaume-Uni
        • Recrutement
        • Charing Cross Hospital
        • Contact:
      • London, Royaume-Uni, NW3 2
        • Recrutement
        • Royal Free London NHS Foundation Trust
        • Contact:
      • Manchester, Royaume-Uni
      • Milton Keynes, Royaume-Uni, MK6 5LD
      • Nottingham, Royaume-Uni
      • Stockton-on-Tees, Royaume-Uni, TS198PE
        • Retiré
        • University Hospital of North Tees
      • Singapore, Singapour, 329563
      • Changhua, Taïwan
        • Recrutement
        • Changhua Christian Hospital (CCH)
        • Contact:
      • Kaohsiung City, Taïwan
        • Recrutement
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
        • Contact:
      • Tainan, Taïwan
        • Recrutement
        • National Cheng Kung University Hospital
        • Contact:
      • Taipei, Taïwan
        • Recrutement
        • National Taiwan University Hospital
        • Contact:
      • Taipei, Taïwan
        • Recrutement
        • Tri-Service General Hospital
        • Contact:
      • Taipei, Taïwan
        • Recrutement
        • Koo Foundation Sun Yat-Sen Cancer Center
        • Contact:
      • Taoyuan City, Taïwan
      • Ankara, Turquie (Türkiye)
        • Recrutement
        • Ankara University Medical Faculty Medical Oncology Department
        • Contact:
      • Bursa, Turquie (Türkiye)
        • Recrutement
        • Uludag University Faculty of Medicine Hospital
        • Contact:
      • Edirne, Turquie (Türkiye)
      • Izmir, Turquie (Türkiye)
    • Ankara
      • Çankaya, Ankara, Turquie (Türkiye)
    • Istanbul
      • Kadiköy, Istanbul, Turquie (Türkiye)
        • Recrutement
        • Goztepe Prof. Dr. Suleyman Yalcin City Hospital
        • Contact:
      • Çapa, Istanbul, Turquie (Türkiye)
    • Kocaeli
    • İzmir
      • Bornova, İzmir, Turquie (Türkiye)
      • Konak, İzmir, Turquie (Türkiye)
    • Arizona
      • Scottsdale, Arizona, États-Unis, 85259
        • Recrutement
        • Mayo Clinic - Scottsdale
        • Contact:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Numéro de téléphone: 855-776-0015
      • Tucson, Arizona, États-Unis, 85719
        • Recrutement
        • University of Arizona - Cancer Center
        • Contact:
    • California
      • Santa Rosa, California, États-Unis, 95403
        • Recrutement
        • Providence Medical Foundation - Santa Rosa, CA
        • Contact:
    • Florida
      • Jacksonville, Florida, États-Unis, 32224
        • Recrutement
        • Mayo Clinic - Jacksonville
        • Contact:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Numéro de téléphone: 855-776-0015
      • Miami, Florida, États-Unis, 33143
      • Plantation, Florida, États-Unis, 33324
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
    • Kentucky
    • Maryland
      • Baltimore, Maryland, États-Unis, 21231
        • Recrutement
        • Johns Hopkins Kimmel Cancer Center
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02114
      • Boston, Massachusetts, États-Unis, 02215
        • Complété
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, États-Unis, 02115
    • Michigan
      • Grand Rapids, Michigan, États-Unis, 49503
        • Recrutement
        • Cancer and Hematology Centers of Western Michigan
        • Contact:
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55407
        • Complété
        • Allina Health System DBA Virginia Piper Cancer Institute
      • Rochester, Minnesota, États-Unis, 55905
        • Recrutement
        • Mayo Clinic - Rochester
        • Contact:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Numéro de téléphone: 855-776-0015
    • Missouri
      • Kansas City, Missouri, États-Unis, 64111
        • Recrutement
        • Saint Luke's Cancer Institute
        • Contact:
      • St Louis, Missouri, États-Unis, 63110
        • Recrutement
        • Washington University School of Medicine
        • Contact:
    • Nevada
      • Reno, Nevada, États-Unis, 89502
      • Reno, Nevada, États-Unis, 89511-2250
    • New Jersey
      • Belleville, New Jersey, États-Unis, 07109
        • Retiré
        • New Jersey Cancer Care, PA
      • New Brunswick, New Jersey, États-Unis, 08901
    • New Mexico
      • Albuquerque, New Mexico, États-Unis, 87110
        • Pas encore de recrutement
        • Presbyterian Kaseman Hospital
        • Contact:
      • Rio Rancho, New Mexico, États-Unis, 87124
        • Recrutement
        • Presbyterian Rust Cancer Center
        • Contact:
    • New York
      • New York, New York, États-Unis, 10029
        • Recrutement
        • Icahn School of Medicine at Mount Sinai
        • Contact:
      • New York, New York, États-Unis, 10065
        • Recrutement
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
        • Contact:
      • New York, New York, États-Unis, 10011
        • Recrutement
        • The Blavatnik Family - Chelsea Medical Center at Mount Sinai
        • Contact:
    • North Carolina
      • Durham, North Carolina, États-Unis, 27705
        • Recrutement
        • Duke University Medical Center
        • Contact:
    • North Dakota
      • Grand Forks, North Dakota, États-Unis, 58201
        • Complété
        • Altru Health Systems
    • Ohio
      • Cleveland, Ohio, États-Unis, 44106
      • Cleveland, Ohio, États-Unis, 44119
        • Retiré
        • Cleveland Clinic
      • Columbus, Ohio, États-Unis, 42112
        • Recrutement
        • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
        • Contact:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15232
        • Complété
        • University of Pittsburgh Medical Center
    • Texas
      • Houston, Texas, États-Unis, 77030
      • Houston, Texas, États-Unis, 77030
      • Houston, Texas, États-Unis, 77054
        • Recrutement
        • Harris Health System - Smith Clinic
        • Chercheur principal:
          • Ahmed Elkhanany
        • Contact:
    • Washington
      • Seattle, Washington, États-Unis, 98104
        • Retiré
        • Swedish Cancer Institute (SCI)

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Pre- or postmenopausal women or men.

  2. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease.

  3. Histological or cytological confirmation of ER+/HER2 - disease

  4. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer.

  5. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue.

  6. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.

  7. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy.

  8. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

  9. Adequate organ function

  10. Able to swallow tablets

  11. Brain metastases are allowed only if the following 4 parameters hold:

    1. Asymptomatic,
    2. Definitively treated (e.g., radiotherapy, surgery),
    3. Not requiring steroids up to 4 weeks before study treatment initiation, AND
    4. Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).
  12. Able to understand and voluntarily sign a written informed consent before any screening procedures.

  13. Every attempt should be made to obtain a biopsy of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2

Exclusion Criteria:

  1. Lymphangitic carcinomatosis involving the lung.
  2. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.
  3. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  4. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy.
  5. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients
  6. Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).
  7. Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.)
  8. History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec.
  9. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).
  10. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization).
  11. On concomitant strong CYP3A4 inhibitors.
  12. On strong and moderate CYP3A4 inducers.
  13. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption.
  14. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment).
  15. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  16. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.
  17. Positive serum pregnancy test (only if premenopausal).
  18. Sexually active premenopausal women and men unwilling to use double-barrier contraception.
  19. Women who are breast feeding
  20. History of non-compliance to medical regimens.
  21. Unwilling or unable to comply with the protocol.
  22. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.
  23. Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels >880 mg/dL at screening.
  24. Fasting triglyceride level >300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
  25. Fasting cholesterol level >400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Treatment

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day

Comparateur actif: Reference Therapy

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression free survival (PFS)
Délai: Within approximately 3 years

PFS is defined as the time from the date of randomization [Visit 0 (Day 1)] to the earliest date of first documented progression per RECIST 1.1 as determined by BICR or death due to any cause.

Within approximately 3 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Objective response rate (ORR)
Délai: Within approximately 3 years

ORR is defined as the percentage of subjects with measurable disease at baseline whose best overall response is either a confirmed CR or a confirmed PR according to RECIST 1.1.

Within approximately 3 years
Overall survival (OS)
Délai: Within approximately 3 years

Overall survival is defined as time from the date of Visit 0 (Day 1) to death due to any cause.

Within approximately 3 years
Clinical benefit rate (CBR)
Délai: Within approximately 3 years

CBR is defined as the percentage of subjects with best overall response of confirmed CR, confirmed PR, or stable disease (SD) with a duration of 24 weeks or longer according to RECIST 1.1. As used in this calculation, stable disease is defined as stable disease in those subjects with measurable disease plus nonPR/non progressive disease (PD) in subjects with non-measurable disease.

Within approximately 3 years
Duration of response (DoR) in subjects with an objective response
Délai: Within approximately 3 years

DoR is from the date of first documented confirmed response (CR or PR) to the date of first documented progression of disease or death due to any cause, whichever is earlier.

Within approximately 3 years
Time to response (TTR) in subjects with an objective response
Délai: Within approximately 3 years

TTR is from the date of randomization to the date of first documented confirmed response (CR or PR).

Within approximately 3 years
Time to cytotoxic chemotherapy
Délai: Within approximately 3 years

From the date of randomization to the date of first documented use of cytotoxic chemotherapy.

Within approximately 3 years
Quality of Life (QoL) evaluated using the Functional Assessment of Cancer Therapy-Breast Cancer-Endocrine Subscale (FACT B-ES)
Délai: Within approximately 3 years

Scale ranges from 'Not at all' to 'Very much'

Within approximately 3 years
Incidence of Adverse Events (AEs) and Serious AEs
Délai: Within approximately 3 years

The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assessed at each visit

Within approximately 3 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

31 octobre 2023

Achèvement primaire (Estimé)

1 avril 2027

Achèvement de l'étude (Estimé)

1 avril 2028

Dates d'inscription aux études

Première soumission

13 janvier 2023

Première soumission répondant aux critères de contrôle qualité

13 janvier 2023

Première publication (Réel)

25 janvier 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner